Clinical Relevance of P-Glycoprotein in Drug Therapy

Drug Metabolism Reviews

Volumn 35, Issue 4, 2003, Pages 417-454

  Lin, Jiunn H ^a   Yamazaki, Masayo ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brain uptake; Cancer chemotherapy; Drug absorption; P Glycoprotein; P Glycoprotein mediated drug interaction

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRICODAR; CHLORPROMAZINE; CYCLOSPORIN A; DAUNORUBICIN; DIGOXIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; FLUOROURACIL; FLUOROURIDINE; GLYCOPROTEIN P; METHOTREXATE; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROGESTERONE; RIFAMPICIN; TARIQUIDAR; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CAPILLARY; CANCER CHEMOTHERAPY; CAPILLARY ENDOTHELIUM; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HYPERBILIRUBINEMIA; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN;

EID: 0347623323     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120026871     Document Type: Conference Paper

References (146)

1. Adams, J. M., Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326.
2. Amidon, G. L. (1983). Determination of intestinal wall permeability. In: Crouthamel, W., Sarapu, A. C., eds. Animal Models for Oral Drug Delivery in Man: In Situ and In Vivo Approaches. Washington, DC: American Pharmaceutical Association, Academy of Pharmaceutical Sciences, 1-25.
3. Artursson, P., Karlsson, J. (1991). Correlation between drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885.
4. Artursson, P., Palm, K., Luthman, K. (1996). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Delivery Rev. 22:67-84.
5. Ashkenazi, A., Dixit, V. M. (1998). Death receptors: signaling and modulation. Science 281:1305-1308.
6. Atack, J. R., Rapoport, S. I., Shapiro, M. B. (1998). Cerebrospinal fluid production is normal in down syndrome. Neurobiol. Aging 19:307-309.
7. Augustijins, P. F., Bradshaw, T. P., Gan, L. S. L., Hendren, D. R., Thakker, D. R. (1993). Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport. Biochem. Biophys. Res. Commun. 197:360-365.
8. Avendano, C., Menendez, J. C. (2002). Inhibitors of multidrug resistance to antitumor agents (MDR). Current Med. Chem. 9:159-193.
9. Backman, J. T., Olkkola, K. T., Neuvonen, P. J. (1996). Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59:7-13.
10. Beck, W. T. (1987). The cell biology of multiple drug resistance. Biochem. Pharmacol. 36:2879-2887.
11. Beck, W. T. (1990). Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat. Rev. 17(suppl. A):11-20.
12. Begley, D. J., Khan, E. U., Rollinson, C., Abbott, J., Regina, A., Roux, F. (2000). The role of brain extracellular fluid production and efflux mechanisms in drug transport to the brain. In: Begley, D. J., Bradbury, M. W., Kreuter, J., eds. The Blood-Brain Barrier and Drug Delivery to the CNS. New York: Marcel Dekker, Inc., 93-108.
13. Benet, L. Z., Cummins, C. L. (2001). The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Del. Rev. 50:S3-S11.
14. Benet, L. Z., Wu, C.-Y., Hebert, M. F., Wacher, V. J. (1996). Intestinal drug metabolism and anti-transport processes: a potential paradigm shift in oral drug delivery. J. Control. Release 39:139-143.
15. Berger, S. H., Jehn, C. H., Johnson L. F., Berger, F. G. (1985). Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 28:461-467.
16. Bertilsson, L., Braithwaite, R., Tybring, G., Garle, M., Borga, O. (1979). Techniques for plasma protein binding of demethylchlorimpipramine. Clin. Pharmacol. Ther. 26:265-271.
17. Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., Bleehen, N. M. (1996). Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:610-618.
18. Brightman, M. W. (1988). The anatomic basis of the blood-brain barrier. In: Neuwelt, E. A., ed. Implications of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects. Vol. 1. New York: Plenum, 53-83.
19. Burton, P. S., Conaradi, R. A., Hilgers, A. R., Ho, N. F. H. (1993). Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:760-766.
20. Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., Bates, S. E. (1997). Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi. Clin. Cancer Res. 3:545-552.
21. 1-antagonists. Drug Metab. Dispos. 31:312-318.
22. Chico, I., Kang, M. H., Bergan, R., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R., Choyke, P., Merino, M., Goldspiel, B., Smith, T., Steinberg, S., Figg, W. D., Fojo, T., Bates, S. (2001). Phase I study of infusion paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J. Clin. Oncol. 19:832-842.
23. Chikhale, E. G., Ng, K.-Y., Burton, P. S., Borchardt, R. T. (1994). Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm. Res. 11:412-419.
24. Childs, S., Yeh, R. L., Hui, D., Ling, V. (1998). Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58:4160-4167.
25. Chishty, M., Reichel, A., Siva, J., Abbott, N. J., Begley, D. J. (2001). Affinity for P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side effects of modern antihistamines. J. Drug. Targeting 9:223-228.
26. Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J. J., Wilkinson, G. R., Kim, R. B., (2000). Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655-660.
27. Chou, R. C., Levy, G. (1981). Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. J. Pharmacol. Exp. Ther. 210:42-48.
28. Cisternino, S., Rousselle, C., Lorico, A., Rappa, G., Scherrmann, J-M. (2003). Apparent lack of Mrp1-mediated efflux at the luminal site of mouse blood-brain barrier endothelial cells. Pharm. Res. 20:904-909.
29. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., Deeley, R. G. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:5902-5910.
30. Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., Bertino, J. R. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-698.
31. Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., Melamed, M. R. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277-1287.
32. Dantzig, A. H., de Alwis, D. P., Burgess, M. (2003). Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Del. Rev. 55:133-150.
33. Deffie, A. M., Batra, J. K., Goldenberg, G. J. (1989). Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive- and resistant P 388 leukemia cell lines. Cancer Res. 49:58-62.
34. Drescher, S., Glaeser, H., Murdter, T., Hitzl, M., Eichelbaum, M., Fromm, M. F. (2003). P-Glycoprotein-mediated intestinal and biliary transport in humans. Clin. Pharmacol. Ther. 73:223-231.
35. Dumontet, C., Sikic, B. I. (1999). Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17:1061-1070.
36. Efferth, T., Osieka, R. (1993). Clinical relevance of the MDR1gene and its gene product, P-glycoprotein, for cancer chemotherapy: a meta-analysis. Tumordiagn. u. Ther. 14:238-243.
37. Evan, G., Littlewood, T. (1998). A matter of life and cell death. Science 281:1317-1321.
38. Filipits, M., Suchomel, R. W., Dekan, G., Stigibauer, W., Haider, K., Depisch, D., Pirker, R. (1997). Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinoma. Br. J. Cancer 75:208-212.
39. Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W. J. F., Eeltink, C., Vermorken, J. B., Pinedo, H. M. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin inpatients with solid tumors. Clin. Cancer Res. 3:2005-2015.
40. Giannakakou, P., Sackett, D. L., Kang, Y.-K., Zhan, Z., Buters, J. T. M., Fojo, T., Poruchynsky, M. S. (1997). Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:17118-17125.
41. Gottesman, M. M., Fojo, T., Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2:48-58.
42. Gramatte, T., Oertel, R. (1999). Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin. Pharmacol. Ther. 66:239-245.
43. Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., Kroemer, H. K. (1999). The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104:147-153.
44. Haas, D. W., Stone, J., Clough, L. A., Johnson, B., Spearman, P., Harris, V. L., Nicotera, J., Johnson, R. H., Raffanti, S., Zhong, L., Bergqwist, P., Chamberlin, S., Hoagland, V., Ju, W. D. (2000). Steady state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin. Pharmacol. Ther. 68:367-374.
45. Haas, D. W., Johnson, B., Nicotera, J., Bailey, V. L., Harris, V. L., Bowles, F. B., Raffanti, S., Schranz, J., Finn, T. S., Saah, A. J., Stone, J. (2003). Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob. Agents and Chemother. 47:2131-2137.
46. Haber, M., Burkhart, C. A., Regl, D. L., Madafiglio, J., Norris, M. D., Horwitz, S. B. (1995). Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem. 270:31269-31275.
47. Hausdorff, J., Fisher, G. A., Halsey, J., Collins, H. L., Lum, B. L. Brophy, N. A., Duran, G. E., Nix, D., Pearce, T., Sikic, B. I. (1995). A phase I trial of etoposide with oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance. Proc. Am. Soc. Clin. Oncol. 14:181, Abstract #407.
48. Hegmann, E. J., Bauer, H. C., Kerbel, R. S. (1992). Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52:6969-6975.
49. Hendrikse, N. H., Schinkel, A. H., de Vries, E. G. E., Fluks, E., van der Graaf, W. T. A., Willemsen, A. T. M., Vaalburg, W., Franssen, E. J. F. (1998). Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 124:1413-1418.
50. Hendrikse, N. H., de Vries, E. G. E., Eriks-Fluks, L., van der Graaf, W. T. A., Hospers, G. A. P., Willemsen, A. T. M., Vaalburg, W., Franssen, E. J. F. (1999). A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 59:2411-2416.
51. Hochman, J. H., Chiba, M., Nishime, J., Yamazaki, M., Lin, J. H. (2000). Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 292:310-318.
52. Hochman, J. H., Chiba, M., Yamazaki, M., Tang, C., Lin, J. H. (2001). P-Glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 298:323-330.
53. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean M., Bates, S. E. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61:6635-6639.
54. Horns, R. C., Dower, W. J., Schimke, R. T. (1984). Gene amplification in a leukemia patient treated with methotrexate. J. Clin. Oncol. 2:2-7.
55. Hunter, J., Hirst, B. H., Simmons, N. L. (1993a). Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cells. Pharm. Res. 10:743-749.
56. Hunter, J., Jepson, M. A., Tsuruo, T., Simmons, N. L., Hirst, B. H. (1993b). Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells: kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268:14991-14997.
57. Inaba, M., Johnson, R. K. (1977). Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia. Cancer Res. 37:4629-4634.
58. Inaba, M., Kobayashi, H., Sakurai, Y., Johnson, R. K. (1979). Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 39:2200-2203.
59. Irvine, J. D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J. W., Selick, H. E., Grove, J. R. (1999). MDCK (Madin-Darby Canine Kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:28-33.
60. Jang, S. H., Wientjes, M. G., Au, J. L.-S. (2003). Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. J. Pharmacol. Exp. Ther. 304:773-780.
61. Jann, M. W., Shirley, K. L., Small, G. W. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 41:719-739.
62. Jette, L., Tetu, B., Beliveau, R. (1993). High levels of P-glycoprotein detected in isolated brain capillaries. Biochem. Biophys. Acta 1150:147-154.
63. Johanson, C. E. (1988a). Potential for pharmacologic manipulation of the blood-cerebrospinal fluid barrier. In: Neuwelt, E. A., ed. Implicalions of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects. Vol. 1. New York: Plenum, 223-260.
64. Johanson, C. E. (1988b). Ontogeny and phylogeny of the blood-barrier. In: Neuwelt, E. A., ed., Implications of the Blood-Brain Barrier and its Manipulation: Basic Science Aspects. Vol. 1. New York: Plenum, 157-198.
65. Jones, D. R., Hall, S. D., Branch, R. A., Jackson, E. K., Wilkinson, G. R. (1986). Plasma binding and brain uptake of benzodiazepines. In: Tillement, J.-P., Lindenlaub, E., eds. Protein Binding and Drug Transport. New York: F.K. Schattauer Verlag, 311-332
66. Juliano, R. L., Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem. Biophys. Acta 455:152-162.
67. Kartner, N., Evernden-Porelle, D., Bradley, G., Ling, V. (1985). Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature (London) 316:820-823.
68. Kavallaris, M., Leary, J. A., Barrett, J. A., Friedlander, M. L. (1996). MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Letters 102:7-16.
69. Keep, R. F., Jones, H. C. (1990). A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Dev. Brain Res. 56:47-53.
70. Khaliq, Y., Gallicano, K., Venance, S., Kravcik, S., Cameron, W. (2000). Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 68:637-646.
71. Kim, R. B., Fromm, M. F., Wandel, C., Leak, B., Wood, A. J. J., Roden, D. M., Wilkinson, G. R. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294.
72. Kovarik, J. M., Rigaudy, L., Guerret, M., Gerbeau, C., Rost, K.-L. (1999). Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin. Pharmacol. Ther. 66:391-400.
73. Kusuhara, H., Sugiyama, Y. (2001a). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part I). Drug Discov. Today 6:150-156.
74. Kusuhara, H., Sugiyama, Y. (2001b). Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part II). Drug Discov. Today 6:206-212.
75. Levin, V. A. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:682-684.
76. Lin, J. H., Cocchetto, D., Duggan, D. E. (1987). Protein binding as a primary determinant of the clinical pharmacokinetic properties of nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet. 12:402-432.
77. Lin, J. H., Chiba, M., Baillie, T. A. (1999a). Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol. Rev. 51:135-157.
78. Lin, J. H., Chiba, M., Chen, I.-W., Nishime, J. A., deLuna, F. A., Yamazaki, M., Lin, Y. (1999b). Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats. Evidence of cytochrome P450 3A and P-glycoprotein induction. Drug Metab. Dispos. 27:1187-1193.
79. Lin, J. H., Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetic: clinical implications. Clin. Pharmacokinet. 42:59-98.
80. Lin, T. H., Lin, J. H. (1990). Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. J. Pharmacol. Exp. Ther. 253:45-50.
81. Liu, Y.-Y., Han, T.-Y., Giuliano, A. E., Hansen, N., Cabot, M. C. (2000). Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 275:7138-7143.
82. Liu, Y.-Y., Han, T.-Y., Giuliano, A. R., Cabot, M. C. (2001). Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15:719-730.
83. Loe, D. W., Deeley, R. G., Cole, S. P. C. (1998). Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP). Evidence for cotransport with reduced glutathione. Cancer Res. 58:5130-5136.
84. Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., Sikic, B. I. (1992). Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J. Clin. Oncol. 10:1635-1642.
85. Macey, R. I. (1978). Mathematical models of membrane transport processes. In: Andreoli, R., ed. Physiology of membrane Disorders. New York: Plenum Press, 125-146.
86. Mahar Doan, K. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., Polli, J. W. (2002). Passive permeability and P-glycoprotein mediated efflux differentiate CNS and nonCNS marketed drugs. J. Pharmacol. Exp. Ther. 303:1029-1037.
87. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C. A. M., Ruevekamp-Helmers, M. C., Foot, B. G. J., Schellens, J. H. M. (1999). Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:4559-4563.
88. Mayer, U., Wagenaar, E., Dorobek, B., Benijnen, J. H., Borst, P., Schinkel, A. H. (1997). Full blockade of intestinal P-glycoprotein and extensive inhibition blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 100:2430-2436.
89. McTavish, D., Sorkin, E. M. (1989). Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19-76.
90. Nishino, J., Suzuki, H., Sugiyama, D., Kitazawa, T., Ito, K., Hanano, M., Sugiyama, Y. (1999). Transepithelial transport of organic anions across the choroid plexus: possible involvement of organic anion transporter and multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 290:289-294.
91. Nooter, K. Brutel, de la Riviere, G., Look, M. P., van Wingerden, K. E., Henzen-Logmans, S. C., Scheper, R. J., Flens, M. J., Klijn, J. G. M., Stoter, G., Foekens, J. A. (1997b). The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 76:486-493.
92. Nooter, K., Brutel de la Riviere, G., Klijn, J., Stoter, G., Foekens, J. (1997a). Multidrug resistance protein in recurrent breast cancer. Lancet 349:1885-1886.
93. Nooter, K., Kok, T., Bosman, F. T., van Wingerden, K. E., Stoter, G. (1998). Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of oesophagus and response to pre-operative chemotherapy. Eur. J. Cancer 34:81-86.
94. Olkkola, K. T., Backman, J. T., Neuvonen, P. J. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55:481-485.
95. Ooi, H., Colucci, W. S. (2001). Pharmacological treatment of heart failure. In: Hardamn, J. G., Limbird, L. E., eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill, 901-932.
96. Ozols, R. F., Cunnion, R. E., Klecker, R. W. Jr., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., Young, R. C. (1987). Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:641-647.
97. Pade, V., Stavchansky, S. (1997). Estimation of the relative contribution of transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 14:1210-1215.
98. Pardridge, W. M. (1981). Transport of protein-bound hormones into tissue in vivo. Endocr. Rev. 2:103-123.
99. Pardridge, W. M., Frank, H. J. L., Cornford, E. M., Braun, L. D., Crane, P. D., Oldendorf, W. H. (1981). Neuropeptides and blood-brain barrier. Adv. Biochem. Psychopharmacol. 28:321-328.
100. Polli, J. W., Jarrett, J. L., Studenberg, S. D., Humphreys, J. E., Dennis, S. W., Brouwer, K. R., Woolley, J. L. (1999). Role of P-glycoprotein on CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1206-1212.
101. Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., Serabjit-Singh, C. S. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:620-628.
102. Raffanti, S., Haas, D. W. (2001). Antiretroviral agents. In: Hardamn, J. G., Limbird, L. E., eds. Goodman & Gillman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill, 1349-1380.
103. Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., Piwnica-Worms, D. (1999). Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to blood-cerebrospinal-fluid drug permeability barrier. Proc. Natl. Acad. Sci. USA 96:3900-3905.
104. Rapport, S. I. (1976). Transport in cells and tissues. In: Rapport, S. I., ed. Blood-brain Barrier in Physiology and Medicine. New York: Raven Press, 17-42.
105. Regina, A., Koman, A., Piciotti, M., Hafny, B. E., Center, M. S., Bergmann, R., Couraud, P. O., Roux, F. (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J. Neurochem. 71:705-715.
106. Robinson, P. J., Rapoport, S. I. (1986). Kinetics of protein binding determines rates of uptake of drugs by brain. Am. J. Physiol. 251:R1212-R1220.
107. Rowinsky, E. K., Smith, L., Wang, Y.-M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Stephenson, J. Jr., Harding, M. W., Von Hoff, D. D. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with biricodar (VX-710), a novel agent that reverses multidrug resistance conferred by overexpression of both MDRI and MRP. J. Clin. Oncol. 16:2964-2976.
108. Rowley, M., Kulagowski, J. J., Watt, A. P., Rathbone, D., Stevenson, G. I., Carling, R. W., Baker, R., Marshall, G. R., Kemp, J. A., Foster, A. C., Grimwood, S., Hargreaves, R., Hurley, C., Saywell, E. L., Tricklebank, M. D., Leeson, P. D. (1997). Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem. 40:4053-4068.
109. Sadeque, A. J. M., Wandel, C., He, H., Shah, S., Wood, A. J. J. (2000). Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:231-237.
110. Schellens, J. H. M., Kruytzer, M. F., Vasey, P. A., Harris, A. L., Deplanque, G., Burgess, M., de Alwis, D., O'Callaghan, M., Kaye, S. B., Beijnen, J. H. (2001). Phase I and pharmacokinetic study of the P-glycoprotein inhibitor LY335979 and paclitaxel in patients with solid tumors. Am. Assoc. Cancer Res. 42:535, Abstract #2882.
111. Schimke, R. T. (1984). Gene amplification, drug resistance, and cancer. Cancer Res. 44:1735-1742.
112. Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagnaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M., Borst, P. (1994). Disruption of the mouse mdr la P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
113. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Borst, P. (1995). Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705.
114. Schinkel, A. H., Wagenaar, E., Mol, C. A., van Deemter, L. (1996). P-Glycoprotein in blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-2524.
115. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Sprits, H., van Tellingen, O., Zijlmans, J. M. J. M., Fibbe, W. E., Borst, P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA 94:4028-4033.
116. Seetharaman, S., Barrand, M. A., Maskell, L., Scheper, R. J. (1998). Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 70:1151-1159.
117. Sirotnak, F. M., Moccio, D. M., Kelleher, L. E., Goutas, L. J. (1981). Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res. 41:4447-4452.
118. Sobrero, A. F., Moir, R. D., Bertino, J. R., Handschumacher, R. E. (1985). Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2′-deoxyuridine in HCT-8 human carcinoma line. Cancer Res. 45:3155-3160.
119. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijen, J. H., van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 94:2031-2035.
120. Sparreboom, A., Planting, A. S. T., Jewell, R. C., van der Burg, M. E., van der Gaast, A., de Bruijn, P., Loos, W. J., Nooter, K., Chandler, L. H., Paul, E. M., Wissel, P. S., Verweij, J. (1999). Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10:719-728.
121. Sun, H., Dai, H., Shaik, N., Elmquist, W. F. (2003). Drug efflux transporters in the CNS. Adv. Drug Del. Rev. 55:83-105.
122. Takebayashi, Y., Akiyama, S., Natsugoe, S., Hokita, S., Niwa, K., Kitazono, M., Sumizawa, T., Tani, A., Furukawa, T., Aikou, T. (1998). The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82:661-666.
123. Tamai, I., Tsuji, A. (2000). Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci. 89:1371-1388.
124. Tanaka, H., Mizojiri, K. (1999). Drug-protein binding and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 288:912-918.
125. Tew, K. D., Houghton, P. J., Houghton, J. A. (1993). Modulation of glutathione. In Preclinical and Clinical Modulation of Anticancer Drugs. Boca Raton: CRC press, 13-77.
126. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. (1987). Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA. 84:7735-7738.
127. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. (1989). Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37:159-164.
128. Thomas, H., Steiner, J. A., Mould, G. P., Mellow, G., Stewart, A. J., Norris, D. B., Waterfall, J. F. (2001). A phase IIA pharmacokinetic study of the P-glycoprotein inhibitor, XR9576 in combination with paclitaxel in patients with ovarian cancer. Am. Soc. Clin. Oncol., abstract #288.
129. Trent, J. M., Buick, R. N., Olson, S., Horns, R. C. Jr., Schimke, R. T. (1984). Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J. Clin. Oncol. 2:8-15.
130. Tsuji, A., Terasaki, T., Takabatake, Y., Tenda, Y., Tamai, I., Yamashima, T., Moritani, S., Tsuruo, T., Yamashita, J. (1992). P-Glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427-1437.
131. Tsuruo, T., lida, H., Tsukagoshi, S., Sakurai Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967-1972.
132. Ueda, C. T., Williamson, B. J., Dzindzio, B. S. (1976). Absolute quinidine bioavailability. Clin. Pharmacol. Ther. 20:260-265.
133. Ueda, C. T., Lemaire, M., Gsell, G., Misslin, P., Nussbaumer, K. (1984). Apparent dose dependent oral absorption of cyclosporine A in rats. Biopharm. Drug Dispos. 5:141-151.
134. Unadkat, J. D. (2003). Presentation at AAPS Transporter Workshop. Peachtree, GA, Feb. 10-12.
135. van Asperen, J., van Tellingen, O., Tijssen, F., Schinkel, A. H., Beijnen, J. H. (1999). Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 79:108-113.
136. van de Waterbeemd, H. (2000). Intestinal permeability: prediction from theory. In: Dressman, J. B., Lennernas, H., eds. Oral Drug Absorption: Predictiou and Assessment. New York: Marcel Dekker, Inc., 31-49.
137. Van Zuylen, L., Nooter, K., Sparreboom, A., Verweij, J. (2000). Development of multidrug resistance convertors: sense or nonsense? Invest. New Drugs 18:205-220.
138. Verstuyft, C., Strabach, S., El Morabet, H., Kerb, R., Brinkmann, U., Dubert, L., Jaillon, P., Funck-Brentano, C., Trugnan, G., Becquemont, L. (2003). Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73:51-60.
139. Wandel, C., Kim, R. B., Guengerich F. P., Wood, A. J. J. (2000). Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 28:895-898.
140. Webb, M., Brun, M., McNiven, M., Le Couteur, D., Craft, P. (1998). MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br. J. Haematology 102:710-717.
141. Westphal, K., Weinbrenner, A., Zschiesche, M., Franke, G., Knoke, M., Oertel, R., Fritz, P., von Richter, O., Hachenberg, T., Warzok, R., Kauffmann, H.-M., Schrenk, D., Terhaag, B., Kroemer, H., Siegmund, W. (2000). Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68:345-355.
142. Wetterich, U., Sphn-Langguth, H., Mutschler, E., Terhaag, B., Rosch, W., Langguth, P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514-522.
143. Wijnholds, J., de Lange, E. C. M., Scheffer, G. L., van den Berg, D.-J., Mol, C. A. A. M., van der Valk, M., Schinkel, A. H., Scheper, R. J., Breimer, D. D., Borst, P. (2000). Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105:279-285.
144. Wilson, C. G., Washington, N. (1989). Small intestine: transit and absorption of drugs. In: Wilson, C. G., Washington, N., eds. Physiological Pharmaceutics: Biological Barriers to Drug absorption. Chichester: Ellis Horwood, Ltd., 71-90.
145. Yamazaki, M., Neway, W. E., Ohe, T., Chen, I.-W., Rowe, J. F., Hochman, J. H., Chiba, M., Lin, J. H. (2001). In vitro substrate identification studies for P-glycoprotein mediated transport: species differences and predictability of in vitro results. J. Pharmacol. Exp. Ther. 296:723-735.
146. Yokogawa, K., Takahashi, M., Tamai, I., Konishi, H., Nomura, M., Moritani, S., Miyamoto, K., Tsuji, A. (1999). P-Glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdrla knockout mice. Pharm. Res. 16:1213-1218.